Press Release Archive
Recent Posts
- Cardiac Dimensions Announces Three Major Publications Demonstrating Long-Term Durability, Real-World Performance, and Broad Patient Benefit of the Carillon Mitral Contour System®
July 8, 2026 - William T. Abraham, MD, Joins Cardiac Dimensions as Chief Medical Officer
September 3, 2025 - Cardiac Dimensions Raises $53 Million Series E Financing
March 20, 2025 - Cardiac Dimensions in recent TCT MD publication
March 4, 2025 - New Long-term Results from the CINCH-FMR Post-Market Registry
February 12, 2025 - Single Center Results from 200+ Patients
February 12, 2025 - Cardiac Dimensions in recent MedTech Strategist publication
July 28, 2023 - Cardiac Dimensions Receives Medical Device Regulation (MDR) Certification For Carillon Mitral Contour System
April 25, 2023 - Cardiac Dimensions Raises $35 Million In Series D Financing
January 5, 2023 - Cardiac Dimensions Included in the New 2021 ESC Guidelines for Heart Failure Management
September 22, 2021 - Cardiac Dimensions® Announces Launch of Its Optimized U.S. Pivotal Trial – The EMPOWER Trial
August 20, 2021 - Cardiac Dimensions Announces Two New Meta-Analysis Publications Showing Statistically Significant and Clinically Meaningful Benefits to Heart Failure Patients Suffering from Functional Mitral Regurgitation
April 7, 2021 - Cardiac Dimensions Welcomes Robert White to its Board of Directors
April 6, 2021 - Cardiac Dimensions Announces $17.5 Million Series C Financing to Accelerate Sales Expansion of the Carillon Mitral Contour System
September 29, 2020 - Cardiac Dimensions Announces Australian Therapeutic Goods Administration’s Approval of the Carillon system for the Treatment of Functional Mitral Regurgitation
September 2, 2020 - New Data Confirms Cardiac Dimensions’ Carillon system Shows Favorable Long-Term Survival Rate in Patients with Functional Mitral Regurgitation
February 25, 2020 - REDUCE FMR Study Shows Cardiac Dimensions’ Carillon system Significantly Improves Mitral Regurgitation and Slows Worsening of Heart Failure
September 12, 2019 - Cardiac Dimensions Reaches 1,000 Implants of Carillon system, a Minimally Invasive Treatment for Functional Mitral Regurgitation
July 1, 2019 - New Data Shows The Carillon Mitral Contour System® Is Associated With Improvement In Regurgitant Volume In Patients With Increased Mitral Valve Tenting
June 13, 2019 - New Data Confirms Cardiac Dimensions’ Carillon system Provides Acute Hemodynamic Efficacy in Patients With Functional Mitral Regurgitation
April 26, 2019 - Cardiac Dimensions Appoints Carmelo Mastrandrea as Vice President of Sales
January 15, 2019 - Cardiac Dimensions Announces DRG Reimbursement Code for Carillon Mitral Contour System® in Germany
October 18, 2018 - Cardiac Dimensions Announces Positive Late-Breaking Results for Blinded Clinical Trial of Minimally Invasive Heart Failure Treatment
September 23, 2018 - Cardiac Dimensions Announces Late-Breaking Data to be Presented at The Transcatheter Cardiovascular Therapeutics Conference (TCT) 2018
September 20, 2018
Join our mailing list for invitations to studies along with company announcements.
© 2026 Cardiac Dimensions. All rights reserved.
CAUTION: USA: Investigational device. Limited by Federal (or United States) law to investigational use.
Canada: Investigational device. To be used by qualified investigators only.
Cardiac Dimensions, Carillon, Carillon Mitral Contour System are registered trademarks of Cardiac Dimensions Pty Ltd.
The Carillon Mitral Contour System is CE Marked (0344) and is commercially available in Europe and other countries.
© 2026 Cardiac Dimensions. All rights reserved.
CAUTION: USA: Investigational device. Limited by Federal (or United States) law to investigational use.
Canada: Investigational device. To be used by qualified investigators only.
Cardiac Dimensions, Carillon, Carillon Mitral Contour System are registered trademarks of Cardiac Dimensions Pty Ltd.
The Carillon Mitral Contour System is CE Marked (0344) and is commercially available in Europe and other countries.